Metropolitan Life Insurance Company (MetLife)’s Stemline Therapeutics, Inc. STML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q2 | – | Sell |
-13,714
| Closed | -$66.4K | – | 2632 |
|
|
2020
Q1 | $66.4K | Buy |
13,714
+1,729
| +14% | +$11.2K | ﹤0.01% | 2276 |
|
|
2019
Q4 | $127K | Sell |
11,985
-1,373
| -10% | -$13.6K | ﹤0.01% | 2183 |
|
|
2019
Q3 | $139K | Hold |
13,358
| – | – | ﹤0.01% | 2121 |
|
|
2019
Q2 | $205K | Hold |
13,358
| – | – | ﹤0.01% | 1878 |
|
|
2019
Q1 | $172K | Buy |
13,358
+4,835
| +57% | +$54.7K | ﹤0.01% | 2004 |
|
|
2018
Q4 | $81K | Hold |
8,523
| – | – | ﹤0.01% | 2403 |
|
|
2018
Q3 | $141K | Hold |
8,523
| – | – | ﹤0.01% | 2242 |
|
|
2018
Q2 | $137K | Buy |
8,523
+434
| +5% | +$7.75K | ﹤0.01% | 2159 |
|
|
2018
Q1 | $124K | Hold |
8,089
| – | – | ﹤0.01% | 2179 |
|
|
2017
Q4 | $126K | Sell |
8,089
-7,674
| -49% | -$103K | ﹤0.01% | 2182 |
|
|
2017
Q3 | $175K | Buy |
+15,763
| New | +$148K | ﹤0.01% | 2335 |
|
|
2015
Q2 | – | Sell |
-12,765
| Closed | -$185K | – | 2716 |
|
|
2015
Q1 | $185K | Buy |
+12,765
| New | +$195K | ﹤0.01% | 2099 |
|
|
2014
Q2 | – | Sell |
-7,976
| Closed | -$162K | – | 2827 |
|
|
2014
Q1 | $162K | Hold |
7,976
| – | – | ﹤0.01% | 2587 |
|
|
2013
Q4 | $156K | Hold |
7,976
| – | – | ﹤0.01% | 2618 |
|
|
2013
Q3 | $361K | Hold |
7,976
| – | – | ﹤0.01% | 1979 |
|
|
2013
Q2 | $190K | Buy |
+7,976
| New | +$127K | ﹤0.01% | 2386 |
|
Metropolitan Life Insurance Company (MetLife)'s STML Position: Q2 2020 in Review
Metropolitan Life Insurance Company (MetLife) sold out of Stemline Therapeutics, Inc. (STML) in Q2 2020, closing a stake of 13,714 shares — an estimated $66.4K sold.
Metropolitan Life Insurance Company (MetLife) first reported a position in STML in Q2 2013 and held it in 16 quarters. The position peaked at $361K in Q3 2013. 0 funds tracked by Wall St. Rank hold STML as of Q2 2020.
- Metropolitan Life Insurance Company (MetLife) reported no remaining Stemline Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
- Metropolitan Life Insurance Company (MetLife) sold 13,714 Stemline Therapeutics, Inc. shares in Q2 2020, an estimated $66.4K.
- Metropolitan Life Insurance Company (MetLife) first reported a position in Stemline Therapeutics, Inc. in Q2 2013 and held it in 16 quarters.
- Metropolitan Life Insurance Company (MetLife)'s Stemline Therapeutics, Inc. position peaked at $361K in Q3 2013.
- 0 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2020.
Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2020, filed 14 Aug 2020.